



Antimicrobial Properties of Green Synthesized Nanomaterials

Guest Editor:

Dr. Ernestina Castro-Longoria

Department of Microbiology,
Center for Scientific Research
and Higher Education of
Ensenada (CICESE), Ensenada
22860, Baja California, Mexico

Deadline for manuscript
submissions:

closed (31 December 2023)

Message from the Guest Editor

Dear Colleagues,

Antimicrobial resistance is a global health problem; in recent decades, nanotechnology has contributed with possible alternatives to control the ability of microorganisms to withstand conventional antimicrobial treatments. It is well documented that metallic nanoparticles (NPs) possess antifungal, antiviral, antiparasitic, and antibacterial properties. However, their application to fight antimicrobial resistance may be limited by the cytotoxic effect they may have on animal cells. Therefore, more research is needed to determine safe concentrations for host cells, while maintaining the antimicrobial effect.

For many years, the most studied NPs for biomedical applications have been gold and silver. However, in the last decade, research has been extended to different nanomaterials in order to find alternatives with greater biocompatibility, less cytotoxicity and immunogenicity effects. This Special Issue seeks manuscript submissions that further explore and document the potential applications of green synthesized nanomaterials as antimicrobial agents.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi